Advertisement

Advertisement

Prostate Cancer

Novel Androgen-Deprivation Therapy With Relugolix Causes Fewer Cardiac Events Than Leuprolide in Advanced Prostate Cancer

Men with prostate cancer on androgen-deprivation therapy are usually treated with leuprolide, a long-acting injectable luteinizing hormone-releasing hormone (LHRH) agonist requiring an every-3-month injection, but it may be possible for ADT to be delivered by a daily oral treatment, pending...

Prostate Cancer

Olaparib for Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

On May 19, 2020, olaparib was approved for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer who experienced disease progression after treatment with...

Prostate Cancer

Expert Point of View: Scott T. Tagawa, MD, MS

Discussant Scott T. Tagawa, MD, MS, of Weill Cornell Medicine, New York, agreed that prostate-specific membrane antigen (PSMA)-targeted positron-emission tomography (PET) is the wave of the future, but data on long-term outcomes are needed, he said. “We are all aware of the deficiencies of imaging ...

prostate cancer

Daniel P. Petrylak, MD, on Prostate Cancer: First-in-Human Study of ARV-110 Shows Antitumor Activity

Daniel P. Petrylak, MD, of the Yale Cancer Center, discusses early data on ARV-110, an androgen receptor proteolysis–targeting chimera degrader, demonstrating antitumor activity in metastatic castration-resistant prostate cancer after treatment with enzalutamide and abiraterone (Abstract 3500).

Prostate Cancer

In Biochemically Recurrent Prostate Cancer, PSMA-Targeted PET/CT Imaging May Be Useful

Positron-emission tomography/computed tomography (PET/CT) imaging with the prostate-specific membrane antigen (PSMA)-targeted radiotracer fluorine F-18 DCFPyL (PyL) successfully identified areas of occult metastasis in men with biochemically recurrent metastatic castration-resistant prostate...

Prostate Cancer

IMbassador250 Trial: No Survival Benefit With Atezolizumab and Enzalutamide in Metastatic Prostate Cancer

The addition of the checkpoint inhibitor atezolizumab to enzalutamide failed to improve overall survival compared with enzalutamide alone in men with metastatic castration-resistant prostate cancer in the phase III IMbassador250 trial, according to results presented at the 2020 American Association ...

Prostate Cancer

PSA Level Prior to Salvage Radiotherapy: Tailoring Delivery of ADT to Men With Prostate Cancer Most Likely to Benefit

In a recent article in JAMA Oncology, reviewed in this issue of The ASCO Post, Dess et al present an important analysis to help guide decision-making in the setting of salvage radiotherapy in prostate cancer.1 This secondary analysis assessed the association of prostate-specific antigen (PSA)...

Prostate Cancer

Presalvage Radiotherapy PSA Levels and Outcomes With Long-Term Antiandrogen Therapy in Prostate Cancer

In an analysis from the NRG/RTOG 9601 trial reported in JAMA Oncology,1Robert T. Dess, MD, of the Department of Radiation Oncology, University of Michigan, Ann Arbor, and colleagues found that men with higher prostate-specific antigen (PSA) presalvage radiotherapy levels after prostatectomy had a...

Prostate Cancer
Issues in Oncology

Men of Color Remain Underrepresented in Prostate Cancer Clinical Trials

An analysis of 59 prostate cancer clinical trials based in North America and Europe found that the vast majority of enrollees were non-Hispanic white men, according to a study published by Rencsok et al in Cancer Epidemiology, Biomarkers & Prevention. The proportion of white participants in...

Prostate Cancer

Expert Point of View: Scott T. Tagawa, MD, MS

Discussant Scott T. Tagawa, MD, MS, of Weill Cornell Medicine, New York, congratulated Dr. Hofman and coauthors on this first randomized trial any PSMA-targeted therapy, and was cautiously optimistic about the targeted radioligand treatment being adopted as post-docetaxel therapy in men with...

Prostate Cancer

Lutetium-177–Labeled PSMA-617 Improves PSA Response in First Analysis From TheraP Trial in Metastatic Prostate Cancer

Initial results of the randomized phase II TheraP trial show that therapy directed to prostate-specific membrane antigen (PSMA) with lutetium-177–labeled PSMA-617 (LuPSMA) significantly improved prostate-specific antigen (PSA) response compared with cabazitaxel in men with metastatic...

prostate cancer

Michael J. Morris, MD, on Prostate Cancer: Impact of PSMA-Targeted Imaging on Clinical Management

Michael J. Morris, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III data from the CONDOR trial, which showed that PSMA-targeted PET scans detected and localized occult disease in most men with biochemically recurrent prostate cancer presenting with negative or equivocal conventional imaging findings (Abstract 5501).

Prostate Cancer

Androgen Deprivation With Oral Relugolix vs Leuprolide in Advanced Prostate Cancer: HERO Trial

As reported at the ASCO20 Virtual Scientific Program (Abstract 5602) and in The New England Journal of Medicine by Shore et al, the phase III HERO trial showed sustained castrate testosterone levels and lower risk of major cardiovascular events with the oral gonadotropin-releasing hormone...

prostate cancer

Neal D. Shore, MD, on Prostate Cancer: Relugolix vs Leuprolide for Advanced Disease

Neal D. Shore, MD, of the Carolina Urologic Research Center, discusses phase III results of the HERO study, which showed relugolix achieved castration as early as day 4 and was superior to leuprolide in sustained testosterone suppression, testosterone recovery after discontinuation, and reduction in cardiovascular side effects (Abstract 5602).

Prostate Cancer

Final Overall Survival Analysis of the PROSPER Trial in Nonmetastatic Castration-Resistant Prostate Cancer

In the final overall survival analysis of the phase III PROSPER trial reported at the ASCO20 Virtual Scientific Program (Abstract 5515) and published in The New England Journal of Medicine, Cora N. Sternberg, MD, and colleagues found that enzalutamide plus androgen-deprivation therapy (ADT)...

prostate cancer

Rana R. McKay, MD, on Prostate Cancer: Intense Androgen-Deprivation Therapy Before Radical Prostatectomy

Rana R. McKay, MD, of the University of California, San Diego, discusses the results of a phase II trial of intense neoadjuvant hormone therapy followed by radical prostatectomy in men with high-risk prostate cancer. The data show that 21% of patients had a favorable pathologic response (Abstract 5503).

Breast Cancer
Kidney Cancer
Prostate Cancer

Expert in Clinical Trial Methodology Makes His Mark in Genitourinary Cancer

In 2019, at the ASCO Annual Meeting, Ian Tannock, MD, PhD, DSc, FASCO, was honored with the Allen S. Lichter Visionary Award for his contributions to the fields of genitourinary and breast cancers as well as his efforts to optimize clinical trial design. The title of his lecture was “Clinical...

prostate cancer

David R. Wise, MD, PhD, on Novel Biomarkers in Prostate Cancer: Is Tissue the Issue?

David R. Wise, MD, PhD, of New York University Perlmutter Cancer Center, summarizes three important studies in prostate cancer: circulating tumor cell count as a prognostic marker of PSA response and progression in metastatic castration-sensitive disease; new phenotypic subtypes; and how circulating tumor DNA dynamics associate with treatment response and radiologic progression-free survival (Abstracts 5506, 5507, and 5508).

prostate cancer

Michael S. Hofman, MBBS, on Prostate Cancer: LuPSMA vs Cabazitaxel in Metastatic Castration-Resistant Disease

Michael S. Hofman, MBBS, of the Peter MacCallum Cancer Centre, discusses phase II results from the ANZUP 1603 trial, which showed that in men with docetaxel-treated metastatic castration-resistant prostate cancer, LuPSMA was more active than cabazitaxel, with relatively fewer grade 3 and 4 adverse events and a more favorable PSA progression-free-survival (Abstract 5500).

Pancreatic Cancer
Prostate Cancer

Data From TAPUR Study Cohorts on Olaparib for BRCA-Mutated Advanced Prostate and Pancreatic Cancers

Positive results from two cohorts of the Targeted Agent and Profiling Utilization Registry (TAPUR) study provide real-world evidence to support recent clinical trial data that demonstrate a role for olaparib in the treatment of advanced prostate and pancreatic cancers with BRCA1/2-inactivating...

Prostate Cancer
COVID-19

Do Men Treated With ADT for Prostate Cancer Have a Lower Risk of Acquiring COVID-19?

A study of 4,532 men in the Veneto region of Italy has found that those who were being treated for prostate cancer with androgen-deprivation therapies (ADT) were less likely to develop COVID-19, and if they were infected, their disease tended to be less severe. This research was published by...

Prostate Cancer

FDA Approves Olaparib for HRR Gene–Mutated Metastatic Castration-Resistant Prostate Cancer

On May 19, the U.S. Food and Drug Administration (FDA) approved olaparib (Lynparza) for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene–mutated metastatic castration-resistant prostate cancer who have had disease progression...

Kidney Cancer
Prostate Cancer

Can Pain After Prostatectomy or Nephrectomy Be Managed Without Opioids?

The use of opioids continues to be major issue facing patients with cancer in the United States. Most patients undergoing prostate and kidney removal may be managed effectively without opioids during the postoperative period, according to new data from researchers in Pittsburgh highlighted during a ...

Prostate Cancer

Overall Survival With the Addition of ADT or Brachytherapy Boost to External-Beam Radiotherapy in Patients With Localized Prostate Cancer

In a study reported in the Journal of Clinical Oncology, Jackson et al found that the common practice of omitting androgen-deprivation therapy (ADT) from treatment with external-beam radiotherapy (EBRT) plus a brachytherapy boost (BT) may be associated with poorer overall survival in men with...

Prostate Cancer

FDA Approves Rucaparib in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

On May 15, the U.S. Food and Drug Administration (FDA) granted accelerated approval to rucaparib (Rubraca) for patients with deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer who have been treated with androgen receptor–directed therapy...

Prostate Cancer

PROfound Trial: Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer and Homologous Recombination Repair Gene Alterations

In a phase III trial reported in The New England Journal of Medicine, Johann de Bono, MB, ChB, PhD, and colleagues found that olaparib significantly improved progression-free survival vs hormonal therapy in patients with metastatic castration-resistant prostate cancer who had alterations in the...

Prostate Cancer

Expert Point of View: Dana E. Rathkopf, MD

Study discussant Dana E. Rathkopf, MD, Director of Clinical Research, Prostate Cancer, at Memorial Sloan Kettering Cancer Center, New York, began her presentation by noting that the “complicated” landscape of metastatic prostate cancer can be approached like a chess game. She used a chess analogy...

Prostate Cancer

Upfront Apalutamide Delays Time to Second Progression in Metastatic Castration-Sensitive Prostate Cancer

The addition of apalutamide to androgen-deprivation therapy (ADT) reduced the risk of second disease progression or death (PFS2) by 34% vs ADT alone in patients with metastatic castration-sensitive prostate cancer, in a post hoc analysis of the phase III TITAN trial presented at the 2020...

Prostate Cancer

Statins With or Without Metformin Are Associated With Increased Survival in Patients With High‑Risk Prostate Cancer

A population-based retrospective cohort study involving 12,700 patients found that men with high-risk prostate cancer who took a statin alone or in combination with metformin had reduced all-cause and prostate cancer–specific mortality. The associations between the medications and reduced...

Prostate Cancer

PSA Dynamics and Response to Androgen-Deprivation Therapy

Adaptive treatments based on evolutionary principles may be an effective approach to prostate cancer treatment by preventing the development of drug resistance and prolonging patient survival. In an article in Nature Communications, Brady-Nicholls et al provided a closer look at a model and data...

Prostate Cancer

Postdiagnosis Weight and Mortality in Survivors of Nonmetastatic Prostate Cancer

In a study reported in the Journal of Clinical Oncology, Troeschel et al found that postdiagnosis obesity was associated with higher cardiovascular disease mortality and all-cause mortality, and postdiagnosis weight gain was associated with higher all-cause and prostate cancer–specific mortality in ...

Prostate Cancer
Immunotherapy

T-Cell Responses and Benefit From Treatment With Ipilimumab in Patients With Metastatic Castration-Resistant Prostate Cancer

Although patients with metastatic castration-resistant prostate cancer typically have limited responses to immunotherapy, a subset of patients with pretreatment evidence of active T-cell responses in their tumors experienced prolonged survival following treatment with ipilimumab in a phase II...

Prostate Cancer

PSA Levels Before Salvage Radiotherapy and Outcomes With Long-Term Antiandrogen Therapy in Prostate Cancer

In an analysis from the NRG/RTOG 9601 trial reported in JAMA Oncology, Daniel E. Spratt, MD, and colleagues found that higher prostate-specific antigen (PSA) pre–salvage radiotherapy (SRT) levels after prostatectomy were associated with better overall survival vs lower levels in men with prostate...

Prostate Cancer
Bladder Cancer
Kidney Cancer
Immunotherapy

Brief Highlights on Novel Therapies for Prostate, Bladder, and Kidney Cancers

Attendees gathered at the 2020 Genitourinary Cancers Symposium in San Francisco to hear the latest news about treating patients with cancers of the prostate, bladder, kidneys, and testicles. In addition to the comprehensive coverage of the meeting in The ASCO Post, here are some brief highlights...

Prostate Cancer

Stereotactic Ablative Radiation vs Observation in Oligometastatic Prostate Cancer: ORIOLE Trial

In a phase II trial reported in JAMA Oncology, Phillips et al found that stereotactic ablative radiotherapy (SABR) was associated with improved outcomes vs observation in men with oligometastatic prostate cancer. The benefit was augmented in patients with total consolidation of disease identified...

Prostate Cancer

Gallium-68 PSMA PET/CT Prior to Surgery or Radiotherapy in High-Risk Prostate Cancer

In an Australian phase III trial (proPSMA) reported in The Lancet, Michael S. Hofman, MBBS, and colleagues found that gallium-68 prostate-specific membrane antigen-11 positron-emission tomography/computed tomography (PSMA PET/CT) provided greater accuracy in identifying nodal and distant metastases ...

Prostate Cancer

Effect of Familial and Hereditary Cancer Syndromes on Risk of Prostate Cancer

In a study reported in the Journal of Clinical Oncology, Jennifer L. Beebe-Dimmer, MPH, PhD, and colleagues found that risk of prostate cancer varied according to cancer family history, with the strongest association being observed between family history and early-onset prostate cancer. Study...

Issues in Oncology
Prostate Cancer
Lung Cancer
Breast Cancer
Colorectal Cancer

Patients With Certain Cancers May Be at a Higher Risk for Atrial Fibrillation

People with a history of cancer have an over twofold risk of developing atrial fibrillation, the most common heart rhythm disorder, compared to the general population, according to research presented at the American College of Cardiology’s Annual Scientific Session (Abstract 1216-235). In...

Prostate Cancer

Expert Point of View: Charles G. Drake, MD, PhD

“This is a great study. It is one of the largest series of prostate-specific membrane antigen (PSMA) scans and covers many patient scenarios, including initial staging, restaging after surgery or radiation or hormonal therapy, and re-imaging in advanced disease,” said Charles G. Drake, MD, PhD, a...

Prostate Cancer

PSMA PET/CT May Have Major Impact on Treatment of Patients With Prostate Cancer

Prostate cancer experts speaking at the 2020 Genitourinary Cancers Symposium alluded to the fact that prostate-specific membrane antigen (PSMA) positron-emission tomography (PET)/computed tomography (CT) scanning is more sensitive than conventional imaging for the detection of occult lesions in men ...

Prostate Cancer

Conventionally Fractionated vs Moderate Hypofractionated Radiation Therapy for Localized Prostate Cancer: Long-Term Update

As reported in the Journal of Clinical Oncology by Avkshtol et al, the 10-year update of a single-center trial has confirmed the primary analysis of the study, showing no superiority in 5-year biochemical and/or clinical disease failure rate with moderate hypofractionated intensity-modulated...

Prostate Cancer

Association of Genomic Prostate Score With Adverse Pathology at Radical Prostatectomy After Initial Active Surveillance

In a study reported in the Journal of Clinical Oncology, Daniel W. Lin, MD, and colleagues found that the 17-gene Oncotype DX Genomic Prostate Score was not associated with the finding of adverse pathology among men with prostate cancer undergoing radical prostatectomy after initial active...

Prostate Cancer

Evaluation of Different Methods of Biopsy for the Diagnosis of Prostate Cancer

In a study reported in The New England Journal of Medicine, Ahdoot et al found that combined use of magnetic resonance imaging (MRI)-targeted biopsy and 12-core systematic prostate biopsy led to enhanced detection of prostate cancers vs either approach alone in men with MRI-visible prostate...

Prostate Cancer
Immunotherapy

Expert Point of View: Charles G. Drake, MD, PhD

In an interview with The ASCO Post, Charles G. Drake, MD, PhD, expounded on the results of the COSMIC-021 trial. Dr. Drake is Division Director for GU Oncology, Co-Director of the Cancer Immunotherapy Program, and Co-Leader of the Tumor Biology and Microenvironment Program at the Herbert Irving...

Prostate Cancer
Immunotherapy

Novel Combination of Cabozantinib Plus Atezolizumab Shows Benefit in Patients With Advanced Prostate Cancer

The combination of the small-molecule tyrosine kinase inhibitor cabozantinib (inhibits VEGF, AXL, MET, and others), plus the immune checkpoint inhibitor atezolizumab achieved encouraging activity in patients with metastatic castration-resistant prostate cancer, according to the results of...

Prostate Cancer

Phenelzine for Biochemical Recurrent Castration-Sensitive Prostate Cancer

A monoamine oxidase A (MAOA) inhibitor in use for decades as an antidepressant demonstrated activity in patients with recurrent prostate cancer, with most toxicities seen with the treatment being reported as mild. These findings were published by Gross et al in Prostate Cancer and Prostatic...

Prostate Cancer

New Guideline Tackles Rapidly Evolving Imaging Strategies for Advanced Prostate Cancer

Advances in radiology and molecular imaging have the potential to significantly change how clinicians diagnose, stage, and monitor response to therapy in patients with prostate cancer. However, there are limited data comparing these next-generation imaging modalities to each other and to...

Prostate Cancer

ASCO Endorses Cancer Care Ontario Guideline on Bone Health and Bone-Targeted Therapies for Prostate Cancer

ASCO recently endorsed the Cancer Care Ontario (CCO) guideline “Bone Health and Bone-Targeted Therapies for Prostate Cancer,” which was originally approved by CCO in 2017.1 The recommendations were based on a systematic review and meta-analysis of relevant research and clinical trial reports...

Prostate Cancer

PSA-Stratified Screening for Prostate Cancer

Previous studies have shown that men with low prostate-specific antigen (PSA) levels (< 1.0 ng/mL) between ages 44 to 60 have a very low risk of developing prostate cancer in the future. A study published by Heijnsdijk et al in JNCI: Journal of the National Cancer Institute investigated benefits ...

prostate cancer

Nicholas D. James, PhD, MBBS, on Adding Abiraterone to Hormone Therapy in Prostate Cancer: STAMPEDE Trial on Cost-Effectiveness

Nicholas D. James, PhD, MBBS, of The Institute of Cancer Research in London, discusses the health economics of adding abiraterone to first-line, long-term hormone therapy in prostate cancer, and what it means for long-term survival, quality-adjusted survival, and cost-effectiveness (Abstract 204).

Advertisement

Advertisement

Advertisement